Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

The Column Group

Investor type Venture Capital
Founders Adriana Tajonar Peter Svennilson

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 100
Average round size
info
The average size of a deal this fund participated in
$58M
Portfolio companies 39
Rounds per year 6.25
Lead investments 18
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.61
Exits 15
Key employees 5
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity
Seed

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical
Summary

In 2006 was created The Column Group, which is appeared as VC. The fund was located in North America if to be more exact in United States. The leading representative office of defined VC is situated in the San Francisco.

The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the The Column Group, startups are often financed by Topspin Partners, OrbiMed, OUP (Osage University Partners). The meaningful sponsors for the fund in investment in the same round are OUP (Osage University Partners), Celgene, Versant Ventures. In the next rounds fund is usually obtained by Kleiner Perkins, Foresite Capital, Venrock.

The top amount of exits for fund were in 2019. The important activity for fund was in 2015. Comparing to the other companies, this The Column Group performs on 10 percentage points less the average number of lead investments. Deals in the range of 10 - 50 millions dollars are the general things for fund. Speaking about the real fund results, this VC is 14 percentage points more often commits exit comparing to other organizations. The fund is constantly included in 2-6 deals per year.

This organization was formed by Adriana Tajonar, Peter Svennilson. The overall number of key employees were 6.

For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Among the most successful fund investment fields, there are Health Care, Medical Device. Among the various public portfolio startups of the fund, we may underline Flexus Biosciences, NGM Biopharmaceuticals, Surrozen The fund has no exact preference in a number of founders of portfolio startups. In case when startup counts 4 of the founder, the chance for it to get the investment is meager. Besides, a startup needs to be aged 2-3 years to get the investment from the fund.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of The Column Group:
Typical Co-investors
The Column Group is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after The Column Group:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Carmot Therapeutics

Biotechnology
Health Care
Therapeutics
$160M26 Jul 2022 San Francisco, California, United States

Remix Therapeutics

Biotechnology
Health Care
Medical
Therapeutics
$70M17 May 2022 Cambridge, Massachusetts, United States

Plexium

Biotechnology
Health Care
Medical
Pharmaceutical
Therapeutics
$102M23 Feb 2022 San Diego, California, United States

Kallyope

Biotechnology
Health Care
Medical
Pharmaceutical
$236M15 Feb 2022 New York, New York, United States

Eikon Therapeutics

Biotechnology
Health Care
Life Science
Medical
$518M06 Jan 2022 Hayward, California, United States

Hexagon Bio

Biotechnology
Therapeutics
$61M22 Sep 2021 California, United States

Obsidian Therapeutics

Biotechnology
Health Care
Pharmaceutical
$115M09 Sep 2021 Cambridge, Massachusetts, United States

Effector Therapeutics

Biotechnology
Health Care
Medical
$60M26 Aug 2021 San Diego, California, United States

Atavistik Bio

Biotechnology
$60M24 Aug 2021 Cambridge, Massachusetts, United States
News
Hexagon Bio Raises $61 Million to Advance Novel Small-Molecule Medicines Mined from Microbial Genomes

– Hexagon Bio, a biopharmaceutical company pioneering the discovery of medicines encoded in the global metagenome, announced that it has raised $61 million to fuel the continued development of its platform to design and develop new therapeutics mined from microbial genomes.
Nextech Invest led the financing, with participation from new investors SoftBank Vision Fund 2* and Casdin Capital, as well as existing investors The Column Group, 8VC, and Two Sigma Ventures.
– Hexagon’s interdisciplinary platform combines technological advances and proprietary insights across machine learning, genomics, synthetic biology and automation to systematically discover new chemical compounds linked to known protein targets.
– Hexagon has built a database of microbial genomes that is more than twice the size of all public databases and is adding thousands of additional genomes per month.

Atavistik Bio Announces $60 Million Series A Financing to Advance Genetically-Validated Targets in Metabolic Diseases and Cancer

– Atavistik Bio, a pre-clinical biotechnology company pioneering the identification of metabolite-protein interactions that have the potential to lead to the discovery and development of first-in-class drug candidates powered by distinct allosteric control mechanisms, announced that the closing of a $60 million Series A financing round.
– The financing was led by The Column Group and joined by Lux Capital, and Nextech Invest.
– The new financing will support development of Atavistik’s drug discovery platform, and future identification of select drug candidates based on deep knowledge of disease relevant pathways that have evolved over millions of years by nature to be allosterically regulated by metabolites.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent The Column Group?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: